Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM.

Mol Cancer Ther. 2007 Jan;6(1):51-60. Epub 2007 Jan 11.

2.

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.

Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP.

Clin Cancer Res. 2003 Nov 15;9(15):5749-55.

3.

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5. Epub 2002 Aug 20.

4.

Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM.

Anticancer Res. 2002 May-Jun;22(3):1497-504.

PMID:
12168829
5.

Histone deacetylases and cancer: causes and therapies.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK.

Nat Rev Cancer. 2001 Dec;1(3):194-202. Review.

PMID:
11902574
6.

Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.

He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP.

J Clin Invest. 2001 Nov;108(9):1321-30.

7.

Histone deacetylase inhibitors as new cancer drugs.

Marks PA, Richon VM, Breslow R, Rifkind RA.

Curr Opin Oncol. 2001 Nov;13(6):477-83. Review.

PMID:
11673688
8.

Cloning and characterization of a histone deacetylase, HDAC9.

Zhou X, Marks PA, Rifkind RA, Richon VM.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10572-7. Epub 2001 Sep 4.

9.

Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

Richon VM, Zhou X, Rifkind RA, Marks PA.

Blood Cells Mol Dis. 2001 Jan-Feb;27(1):260-4. Review. No abstract available.

PMID:
11358386
10.

The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.

Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP.

Cancer Res. 2001 May 1;61(9):3591-4.

11.

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA.

Clin Cancer Res. 2001 Apr;7(4):962-70.

12.

Inhibitors of histone deacetylase are potentially effective anticancer agents.

Marks PA, Rifkind RA, Richon VM, Breslow R.

Clin Cancer Res. 2001 Apr;7(4):759-60. No abstract available.

13.

Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras.

Zhou X, Richon VM, Wang AH, Yang XJ, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14329-33.

14.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.

Cancer Res. 2000 Sep 15;60(18):5165-70.

15.

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Richon VM, Sandhoff TW, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9.

16.

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

Marks PA, Richon VM, Rifkind RA.

J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6. Review.

PMID:
10922406
17.

Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).

Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM.

Anticancer Res. 1999 Nov-Dec;19(6B):4999-5005.

PMID:
10697502
18.

Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.

Zhou X, Richon VM, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1056-61.

19.

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.

Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP.

Nature. 1999 Sep 9;401(6749):188-93.

PMID:
10490031
20.

Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.

Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP.

Cancer Res. 1999 Sep 1;59(17):4392-9.

21.
22.

Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agents.

Webb Y, Zhou X, Ngo L, Cornish V, Stahl J, Erdjument-Bromage H, Tempst P, Rifkind RA, Marks PA, Breslow R, Richon VM.

J Biol Chem. 1999 May 14;274(20):14280-7.

23.

Hybrid polar inducers of transformed cell differentiation/apoptosis. From the cell to the clinic.

Marks PA, Richon VM, Breslow R, Rifkind RA.

C R Acad Sci III. 1999 Feb-Mar;322(2-3):161-5. Review. No abstract available.

PMID:
10196668
24.

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7.

25.

Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells.

Siegel DS, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon VM, Rifkind RA, Marks PA, Michaeli J.

Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):162-6.

26.
27.

Induced differentiation of cancer cells: second generation potent hybrid polar compounds target cell cycle regulators.

Marks PA, Richon VM, Rifkind RA.

Eur J Cancer Prev. 1996 Dec;5 Suppl 2:75-7. No abstract available.

PMID:
9061298
28.

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5705-8.

29.

Induced differentiation, the cell cycle, and the treatment of cancer.

Rifkind RA, Richon VM, Marks PA.

Pharmacol Ther. 1996;69(2):97-102. Review.

PMID:
8984510
31.

Clinical excellence and research: one and indivisible.

Rifkind RA.

Ann N Y Acad Sci. 1994 Nov 4;729:162-3; discussion 170-4. No abstract available.

PMID:
7998730
32.

Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.

Kiyokawa H, Richon VM, Rifkind RA, Marks PA.

Mol Cell Biol. 1994 Nov;14(11):7195-203.

33.

Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.

Marks PA, Richon VM, Kiyokawa H, Rifkind RA.

Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10251-4. Review.

34.

Differential modulation of protein kinase C isoforms in erythroleukemia during induced differentiation.

Leng L, Yu F, Dong L, Busquets X, Osada S, Richon VM, Marks PA, Rifkind RA.

Cancer Res. 1993 Nov 15;53(22):5554-8.

35.

Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1.

Kiyokawa H, Richon VM, Venta-Perez G, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6746-50.

36.

Differentiating agents for transformed cells.

Michaeli J, Rifkind RA, Marks PA.

Cancer Chemother Biol Response Modif. 1993;14:330-52. Review. No abstract available.

PMID:
8312107
37.

A rise and fall in 1,2-diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis.

Michaeli J, Busquets X, Orlow I, Younes A, Colomer D, Marks PA, Rifkind RA, Kolesnick RN.

J Biol Chem. 1992 Nov 25;267(33):23463-6.

38.

Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.

Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA.

Blood. 1992 Nov 15;80(10):2604-9.

PMID:
1421378
39.
40.

Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.

Kiyokawa H, Ngo L, Kurosaki T, Rifkind RA, Marks PA.

Cell Growth Differ. 1992 Jun;3(6):377-83.

41.

Cloning of a D-type cyclin from murine erythroleukemia cells.

Kiyokawa H, Busquets X, Powell CT, Ngo L, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2444-7.

42.

Protein kinase C isozymes epsilon and alpha in murine erythroleukemia cells.

Powell CT, Leng L, Dong L, Kiyokawa H, Busquets X, O'Driscoll K, Marks PA, Rifkind RA.

Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):147-51.

43.

Differentiating agents in cancer therapy.

Michaeli J, Rifkind RA, Marks PA.

Cancer Chemother Biol Response Modif. 1992;13:286-307. Review. No abstract available.

PMID:
1389912
44.

Potent cytodifferentiating agents related to hexamethylenebisacetamide.

Breslow R, Jursic B, Yan ZF, Friedman E, Leng L, Ngo L, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5542-6.

45.

Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation.

Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1666-70.

46.

Differentiating agents in cancer therapy.

Marks PA, Rifkind RA.

Cancer Chemother Biol Response Modif. 1991;12:291-305. Review. No abstract available.

PMID:
1931448
48.

Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells.

Michaeli J, Lebedev YB, Richon VM, Chen ZX, Marks PA, Rifkind RA.

Mol Cell Biol. 1990 Jul;10(7):3535-40.

49.

Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells.

Melloni E, Pontremoli S, Sparatore B, Patrone M, Grossi F, Marks PA, Rifkind RA.

Proc Natl Acad Sci U S A. 1990 Jun;87(12):4417-20.

50.

Supplemental Content

Loading ...
Support Center